Stocktoria
Skye Bioscience, Inc. SKYE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-02-24
Skye Bioscience, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | — | — | — | $6.0M | $2.9M |
| Operating income | -$58.2M | -$30.2M | -$34.7M | -$18.3M | -$7.8M |
| Interest expense | $0 | $749,308 | $906,270 | $665,133 | $769,159 |
| Income tax | $5,400 | $10,071 | $3,600 | $6,741 | $2,100 |
| Net income | -$55.9M | -$26.6M | -$37.6M | -$19.5M | -$8.5M |
| EPS (diluted) | $-1.41 | $-0.73 | $-5.37 | $-8.77 | $-0.02 |
| Operating cash flow | -$43.1M | -$25.2M | -$14.0M | -$12.7M | -$6.5M |
| Free cash flow | -$43.1M | -$26.8M | -$14.0M | -$12.8M | -$6.6M |
| Cash & equivalents | $5.9M | $68.4M | $1.3M | $1.2M | $9.0M |
| Total assets | $28.3M | $72.8M | $11.9M | $9.1M | $9.9M |
| Total liabilities | $8.3M | $4.6M | $14.1M | $12.1M | $4.0M |
| Shareholders' equity | $20.0M | $68.2M | -$2.1M | -$3.0M | $5.9M |
Source: SEC EDGAR filings · CIK 0001516551 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.